HURA — TuHURA Biosciences Share News
0.000.00%
Last trade - 00:00- $131.28m
- $134.16m
TuHURA Biosciences Inc reports results for the quarter - Earnings Summary
TuHURA Biosciences Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Kintara Therapeutics - Record Date For CVR Issuance Set
Brief: Kintara Therapeutics Provides Update On Corporate Developments And REM-001 Clinical Study
Brief: Tuhura Biosciences Enters Into Exclusivity And Right Of First Offer Agreement For Kineta's KVA12123 Novel Anti-Vista Checkpoint Inhibitor
Brief: Kintara Therapeutics And TuHURA Biosciences Provide Update On Recent Corporate And Clinical Advancements
Brief: Kintara Therapeutics Requests Nasdaq For Additional 180-Day Extension To Regain Compliance With Minimum Bid Price Requirement
U.S. STOCKS ON THE MOVE-Identiv, Levi Strauss, cannabis firms
U.S. STOCKS ON THE MOVE-Spotify, Ulta Beauty, SPAR Group
Kintara Therapeutics doubles on plans to merge with TuHURA Biosciences
U.S. STOCKS ON THE MOVE-Lenz Therapeutics, Intel, ARCA Biopharma
Kintara Therapeutics doubles on plans to merge with TuHURA Biosciences
Brief: Kintara Therapeutics, Tuhura Biosciences Enter Into Merger Agreement
Brief: Kintara Therapeutics Expands REM-001 Clinical Study To Include Patients On Pembrolizumab
Brief: Kintara Therapeutics Announces Initiation Of Rem-001 Clinical Trial
Brief: Kintara Therapeutics Inc Gets Nasdaq Notice On Non-Compliance With $1 Minimum Bid Price Requirement
Brief: Kintara Therapeutics Announces Review Of Strategic Alternatives
Brief: Kintara Therapeutics Granted Extension By Nasdaq To Regain Compliance With The Stockholders' Equity Continued Listing Requirement
Brief: Kintara Therapeutics Announces Preliminary Topline Results From GBM Agile Study